HIV Clinical Pharmacology & Therapeutics Research Training Program

这是一份名为《HIV临床药理学和治疗研究培训》的D43课程的续期申请 (HIVRT)项目，由布法罗大学(UB)和津巴布韦大学(UZ)领导。优化艾滋病毒 用艾滋病毒预防传播准备和治疗作为预防(TasP)，以达到95-95-95和 “流行病”战略。然而，这些方法的成功使用需要继续研究 为指导低收入和中等收入国家的实施而进行的。HIVRT将增加 有资格的调查人员为这项研究工作寻求外部资金。随着替诺福韦的问世， 拉米夫定和多洛替格雷，长效抗逆转录病毒药物(如卡波替格韦，利培韦林)，新的抗逆转录病毒药物(如来那帕韦， 依拉特拉韦)和HIV-1广谱中和抗体(BNAbs)，与之相关的临床和翻译研究 需要新的治疗剂来检查最佳的药代动力学-药效学参数 将防止传播和/或维持病毒载量抑制以及在共病情况下的安全性。 临床医生-科学家和转化型科学家的培训将利用先前 UB-UZ HIVRT和过渡到新设计的研究培训计划。具体目标：1)提供HIVRT 对于博士后(5名)和博士后(5名)受训人员，增加独立研究人员的数量， 资助的方案，重点是艾滋病毒临床药理学和治疗学以及区域公共卫生优先事项 包括新冠肺炎，2)团队科学方面的HIVRT学员导师，以及其他具有以下专业知识的人 药物生物分析、生物医学信息学、数据科学、基因组学和微生物组，3)福斯特 社区支持小组参与创新研究，研究新的艾滋病毒临床 预防、治疗和研究长效的药理学和治疗学策略 抗逆转录病毒、单克隆抗体和传统药物，以及4)提供HIVRT，促进SMART 旨在实现可持续发展目标的学术-公共-私营伙伴关系。实习生将拥有 在亚利桑那州立大学接受强化培训，在此期间，新知识和技能将允许制定一个研究项目， 将在UZ持续监督下进行为期18个月的培训，总共培训两年。这个 该计划将建立在我们之前的Fogarty国际中心艾滋病毒研究培训计划和更早的 AITRP。这些研究培训计划为此次D43续订奠定了基础，其中包括 UZ和UB导师的杰出团队，他们将利用HIV临床提供指导和协作 为艾滋病毒临床和转译研究而建立的药理学和治疗学基金会。这个 课程将通过一个既定的研究和教育培训核心来组织和提供。这个 D43拥有一个出色的外部培训咨询委员会，将有助于实现高效、高效的 津巴布韦艾滋病毒临床药理学和治疗学研究培训倡议。

This is a renewal application for a D43 titled, HIV Clinical Pharmacology and Therapeutics Research Training (HIVRT) program led by the University at Buffalo (UB) and the University of Zimbabwe (UZ). Optimizing HIV prevention of transmission with HIV PReP and treatment as prevention (TasP) to meet 95-95-95 and “ending the epidemic” strategies. However, successful use of these approaches requires that continued research be conducted to guide implementation in low-middle income countries. The HIVRT will increase the number of qualified investigators to seek external funding for this research effort. With the introduction of tenofovir, lamivudine and dolutegravir, long-acting ARVs (e.g., cabotegravir, rilpivirine), new ARVs (e.g., lenacapavir, islatravir) and HIV-1 broadly neutralizing antibodies (bNABs), clinical and translational research related to these new therapeutic agents is needed to examine the optimal pharmacokinetics-pharmacodynamics parameters that will prevent transmission and/or sustain viral load suppression as well as safety in the context of co-morbidities. Training of clinician-scientists and translational scientists will utilize the foundation that has been built by the prior UB-UZ HIVRT and transition to the newly designed research training program. Specific Aims: 1) Provide a HIVRT for pre-doctoral (5) and post-doctoral (5) trainees that increases the number of researchers with independent, funded programs with a focus on HIV clinical pharmacology and therapeutics and regional public health priorities including COVID-19, 2) Mentor HIVRT trainees in team science and that include others with expertise in pharmaceutical bioanalysis, biomedical informatics, data sciences, genomics, and microbiome, 3) Foster community support group engagement to participate in innovative research to study novel HIV clinical pharmacology and therapeutics strategies for prevention and treatment and investigate long-acting antiretrovirals and monoclonal antibodies and traditional medicines, and 4) Provide an HIVRT that fosters smart academic-public-private partnerships aimed at addressing sustainable developmental goals. Trainees will have intensive training at UB during which new knowledge and skills will allow formulation of a research project that will be conducted under continued supervision for 18 months at UZ for a total of two years of training. The program will build on our prior Fogarty International Center HIV Research Training program, and an earlier AITRP. These research training programs provide the foundation for this D43 renewal that includes an outstanding group of UZ and UB mentors who will provide mentoring and collaboration utilizing the HIV Clinical Pharmacology and Therapeutics foundation that has been built for HIV clinical and translational research. The curriculum will be organized and provided through an established Research and Education Training Core. The D43 has an outstanding external Training Advisory Committee that will contribute to a highly productive, efficient HIV Clinical Pharmacology and Therapeutics research training initiative in Zimbabwe.